Motif Bio PLC Results Conference Call Details (4229V)

TIDMMTFB

RNS Number : 4229V

Motif Bio PLC

18 April 2016

Motif Bio plc

("Motif Bio" or the "Company")

Notice of Results

Motif Bio plc (AIM: MTFB), the clinical stage biopharmaceutical company specialising in developing novel antibiotics, will announce its financial results for the year ended 31 December 2015 on Wednesday 20 April 2016.

The Company will hold an analyst and investor conference call at 12:00 BST (07.00 EST) on Wednesday 20 April 2016. The conference call will be hosted by Motif Bio's Chairman Richard Morgan and CEO Graham Lumsden and will cover the Company's full year results which will have been announced earlier in the day. No additional operational or financial information will be disclosed.

The conference call will commence at 12.00 BST (07.00 EST) and is expected to close by 13:00 BST (08.00 EST).

To join the call, participants should dial:

   --              United Kingdom; 0800 368 0649 
   --              United Kingdom (Local); 020 3059 8125 
   --              All Other Locations; +44 20 3059 8125

On joining the call, participants must quote the password 'sciences' to the operator, in order to gain access to the conference.

For further information please contact:

 
 Motif Bio plc                              info@motifbio.com 
  Graham Lumsden (Chief 
  Executive Officer) 
 Zeus Capital Limited (NOMAD 
  & BROKER) 
  Phil Walker/Dan Bate 
  Dominic Wilson                          +44 (0)20 3829 5000 
 Northland Capital Partners 
  Limited (BROKER) 
  Patrick Claridge/ David 
  Hignell 
  John Howes/ Rob Rees (Broking)          +44 (0)203 861 6625 
 
 Walbrook PR Ltd. (FINANCIAL          +44 (0) 20 7933 8780 or 
  PR & IR)                            motifbio@walbrookpr.com 
  Paul McManus                       Mob: +44 (0)7980 541 893 
  Mike Wort                          Mob: +44 (0)7900 608 002 
 
 MC Services AG (EUROPEAN 
  IR) 
  Raimund Gabriel                          +49 (0)89 210 2280

About Motif Bio (www.motifbio.com)

Motif is a clinical-stage biopharmaceutical company, specialising in the development of novel antibiotics that are designed to be effective against serious and life-threatening infections caused by multi-drug resistant bacteria. Our lead product candidate, iclaprim, is being developed for the treatment of the most common and serious bacterial infections such as acute bacterial skin and skin structure infections (ABSSSI) and hospital acquired bacterial pneumonia (HABP), including those caused by resistant strains such as MRSA (methicillin-resistant Staphylococcus aureus). Two Phase III ABSSSI clinical trials are on track to be completed in 2017 and if approved, iclaprim could be ready for commercialization in 2018. The Company is in discussions with pharmaceutical companies and universities to build a pipeline of innovative antibiotics targeting Gram-positive and Gram-negative bacteria.

This information is provided by RNS

The company news service from the London Stock Exchange

END

NORLIFVDSLIRLIR

(END) Dow Jones Newswires

April 18, 2016 02:00 ET (06:00 GMT)

Grafico Azioni Motif Bio (LSE:MTFB)
Storico
Da Giu 2024 a Lug 2024